PAH's Hidden Economic Toll Revealed

A new study has found that pulmonary arterial hypertension, a rare and progressive lung condition, places a significant economic burden on Switzerland, with estimated annual costs of around €48.5 million. The study, which looked at the costs of treating the condition from a societal perspective, found that the majority of these costs were due to medication, with patients in more severe stages of the disease facing even higher costs. The study's findings highlight the need for more effective treatments and management strategies for PAH, not just for patients' health but also for the country's economy.